Search

Your search keyword '"Serratia marcescens drug effects"' showing total 1,182 results

Search Constraints

Start Over You searched for: Descriptor "Serratia marcescens drug effects" Remove constraint Descriptor: "Serratia marcescens drug effects"
1,182 results on '"Serratia marcescens drug effects"'

Search Results

251. Spread of Serratia marcescens coharboring aac(6')-Ib-cr, bla CTX-M, armA, and bla OXA-1 carried by conjugative IncL/M type plasmid in Korean hospitals.

252. Ceramide and cerebrosides from the octocoral Sarcophyton ehrenbergi.

253. Multipurpose solutions and rates of biocidal efficacy.

254. Application of response surface methodology in medium optimization for protease production by the new strain of Serratia marcescens SB08.

255. Kinetic analysis of growth rate, ATP, and pigmentation suggests an energy-spilling function for the pigment prodigiosin of Serratia marcescens.

256. Comparison of 3 alcohol gels and 70% ethyl alcohol for hand hygiene.

257. Growth pattern of Hg resistant bacteria isolated from Kor River in the presence of mercuric chloride.

258. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.

259. Alternative hand contamination technique to compare the activities of antimicrobial and nonantimicrobial soaps under different test conditions.

260. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.

261. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics.

262. How effective are hand antiseptics for the postcontamination treatment of hands when used as recommended?

263. Characterization of the Serratia marcescens SdeCDE multidrug efflux pump studied via gene knockout mutagenesis.

264. Outbreak of multidrug-resistant Serratia marcescens infection in a neonatal intensive care unit.

265. Fimbrolide-coated antimicrobial lenses: their in vitro and in vivo effects.

266. Hexavalent molybdenum reduction to molybdenum blue by S. marcescens strain Dr. Y6.

267. The function of SpnR and the inhibitory effects by halogenated furanone on quorum sensing in Serratia marcescens AS-1.

268. E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.

269. Functional gene cloning and characterization of the SsmE multidrug efflux pump from Serratia marcescens.

270. Synthesis, characterization and biological aspects of novel five-coordinated dimeric-Cu(II) systems.

271. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada.

272. HasB, the Serratia marcescens TonB paralog, is specific to HasR.

273. Microfluidic pump powered by self-organizing bacteria.

274. Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations.

275. First detection of a class 2 integron among clinical isolates of Serratia marcescens.

276. Spontaneous zygogenesis (Z-mating) in mecillinam-rounded bacteria.

277. Fluoroquinolone resistance of Serratia marcescens: sucrose, salicylate, temperature, and pH induction of phenotypic resistance.

278. Serratia marcescens isolated in 2005 from clinical specimens from patients with diminished immunity.

279. Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit.

280. Inhibition of quorum sensing in Serratia marcescens AS-1 by synthetic analogs of N-acylhomoserine lactone.

281. Antimicrobial resistance in 11 hospitals in Puerto Rico: results of an antimicrobial resistance management (ARM) program.

282. A fitness cost associated with the antibiotic resistance enzyme SME-1 beta-lactamase.

283. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.

284. SME-2-producing Serratia marcescens isolate from Switzerland.

285. Site-directed mutagenesis studies to probe the role of specific residues in the external loop (L3) of OmpF and OmpC porins in susceptibility of Serratia marcescens to antibiotics.

286. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.

287. Efficacy of contact lens multipurpose solutions against serratia marcescens.

288. Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens.

289. [Comparison of susceptibilities for fosfomycin determined by various methods in clinical isolates in 2003 -2004].

290. Molecular cloning and characterization of a multidrug efflux pump, SmfY, from Serratia marcescens.

291. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.

293. Case-control analysis of endemic Serratia marcescens bacteremia in a neonatal intensive care unit.

294. Inhibitory effects of d-mannose on trypanosomatid lysis induced by Serratia marcescens.

295. Potentiation of antimicrobial activity of aminoglycosides by carnosol from Salvia officinalis.

296. An ectopic expression screen reveals the protective and toxic effects of Drosophila seminal fluid proteins.

297. Characterization of imipenem-resistant Serratia marcescens producing IMP-type and TEM-type beta-lactamases encoded on a single plasmid.

298. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia.

299. High-level resistance to cobalt and nickel but probably no transenvelope efflux: Metal resistance in the Cuban Serratia marcescens strain C-1.

300. Antibacterial activities of Emblica officinalis and Coriandrum sativum against Gram negative urinary pathogens.

Catalog

Books, media, physical & digital resources